Eudowood Neonatal Pulmonary Division, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Curr Opin Pediatr. 2019 Jun;31(3):330-339. doi: 10.1097/MOP.0000000000000751.
Mutations in genes encoding proteins critical for the production and function of pulmonary surfactant cause diffuse lung disease. Timely recognition and diagnosis of affected individuals is important for proper counseling concerning prognosis and recurrence risk.
Involved genes include those encoding for surfactant proteins A, B, and C, member A3 of the ATP-binding cassette family, and for thyroid transcription factor 1. Clinical presentations overlap and range from severe and rapidly fatal neonatal lung disease to development of pulmonary fibrosis well into adult life. The inheritance patterns, course, and prognosis differ depending upon the gene involved, and in some cases the specific mutation. Treatment options are currently limited, with lung transplantation an option for patients with end-stage pulmonary fibrosis. Additional genetic disorders with overlapping pulmonary phenotypes are being identified through newer methods, although these disorders often involve other organ systems.
Genetic disorders of surfactant production are rare but associated with significant morbidity and mortality. Diagnosis can be made invasively through clinically available genetic testing. Improved treatment options are needed and better understanding of the molecular pathophysiology may provide insights into treatments for other lung disorders causing fibrosis.
编码肺表面活性剂产生和功能所必需的蛋白的基因突变可导致弥漫性肺部疾病。及时识别和诊断受影响个体对于适当的预后和复发风险咨询非常重要。
涉及的基因包括编码肺表面活性剂蛋白 A、B 和 C、ATP 结合盒家族成员 A3 和甲状腺转录因子 1 的基因。临床表现重叠,范围从严重且迅速致命的新生儿肺部疾病到成年后发展为肺纤维化。遗传模式、病程和预后取决于所涉及的基因,在某些情况下还取决于特定的突变。目前治疗选择有限,肺移植是终末期肺纤维化患者的一种选择。通过新方法发现了具有重叠肺部表型的其他遗传疾病,尽管这些疾病通常涉及其他器官系统。
肺表面活性剂产生的遗传疾病很少见,但与显著的发病率和死亡率相关。通过临床可用的基因检测可进行有创诊断。需要改进治疗选择,对分子病理生理学的更好理解可能为治疗其他导致纤维化的肺部疾病提供思路。